Elicio presents path forward for ELI-002 7P in PDAC
Elicio Therapeutics is disclosing the clinical roadmap for ELI-002 7P in metastatic pancreatic ductal adenocarcinoma. The company outlines the planned Phase 1 study evaluating combination therapy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day